IBDEI0B6 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5040,1,3,0)
 ;;=3^Tachycardia,Unspec
 ;;^UTILITY(U,$J,358.3,5040,1,4,0)
 ;;=4^R00.0
 ;;^UTILITY(U,$J,358.3,5040,2)
 ;;=^5019163
 ;;^UTILITY(U,$J,358.3,5041,0)
 ;;=R07.9^^27^326^8
 ;;^UTILITY(U,$J,358.3,5041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5041,1,3,0)
 ;;=3^Chest Pain,Unspec
 ;;^UTILITY(U,$J,358.3,5041,1,4,0)
 ;;=4^R07.9
 ;;^UTILITY(U,$J,358.3,5041,2)
 ;;=^5019201
 ;;^UTILITY(U,$J,358.3,5042,0)
 ;;=I20.0^^27^326^19
 ;;^UTILITY(U,$J,358.3,5042,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5042,1,3,0)
 ;;=3^Unstable Angina
 ;;^UTILITY(U,$J,358.3,5042,1,4,0)
 ;;=4^I20.0
 ;;^UTILITY(U,$J,358.3,5042,2)
 ;;=^5007076
 ;;^UTILITY(U,$J,358.3,5043,0)
 ;;=I20.9^^27^326^1
 ;;^UTILITY(U,$J,358.3,5043,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5043,1,3,0)
 ;;=3^Angina Pectoris,Unspec
 ;;^UTILITY(U,$J,358.3,5043,1,4,0)
 ;;=4^I20.9
 ;;^UTILITY(U,$J,358.3,5043,2)
 ;;=^5007079
 ;;^UTILITY(U,$J,358.3,5044,0)
 ;;=I31.9^^27^326^16
 ;;^UTILITY(U,$J,358.3,5044,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5044,1,3,0)
 ;;=3^Pericardium Disease,Unspec
 ;;^UTILITY(U,$J,358.3,5044,1,4,0)
 ;;=4^I31.9
 ;;^UTILITY(U,$J,358.3,5044,2)
 ;;=^5007165
 ;;^UTILITY(U,$J,358.3,5045,0)
 ;;=I49.9^^27^326^2
 ;;^UTILITY(U,$J,358.3,5045,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5045,1,3,0)
 ;;=3^Arrhythmia,Cardiac,Unspec
 ;;^UTILITY(U,$J,358.3,5045,1,4,0)
 ;;=4^I49.9
 ;;^UTILITY(U,$J,358.3,5045,2)
 ;;=^5007237
 ;;^UTILITY(U,$J,358.3,5046,0)
 ;;=I13.0^^27^326^9
 ;;^UTILITY(U,$J,358.3,5046,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5046,1,3,0)
 ;;=3^HTN Hrt Disease w/ Hrt Failure and CKD,Stage 1-4
 ;;^UTILITY(U,$J,358.3,5046,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,5046,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,5047,0)
 ;;=I13.2^^27^326^10
 ;;^UTILITY(U,$J,358.3,5047,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5047,1,3,0)
 ;;=3^HTN Hrt Disease w/ Hrt Failure and CKD, Stage 5 or ESRD
 ;;^UTILITY(U,$J,358.3,5047,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,5047,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,5048,0)
 ;;=I13.10^^27^326^11
 ;;^UTILITY(U,$J,358.3,5048,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5048,1,3,0)
 ;;=3^HTN Hrt Disease w/o Hrt Failure and CKD, Stage 1-4
 ;;^UTILITY(U,$J,358.3,5048,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,5048,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,5049,0)
 ;;=I13.11^^27^326^12
 ;;^UTILITY(U,$J,358.3,5049,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5049,1,3,0)
 ;;=3^HTN Hrt Disease w/o Hrt Failure and CKD,Stage 5 or ESRD
 ;;^UTILITY(U,$J,358.3,5049,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,5049,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,5050,0)
 ;;=I50.1^^27^326^15
 ;;^UTILITY(U,$J,358.3,5050,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5050,1,3,0)
 ;;=3^Left Ventricular Failure
 ;;^UTILITY(U,$J,358.3,5050,1,4,0)
 ;;=4^I50.1
 ;;^UTILITY(U,$J,358.3,5050,2)
 ;;=^5007238
 ;;^UTILITY(U,$J,358.3,5051,0)
 ;;=E21.3^^27^327^17
 ;;^UTILITY(U,$J,358.3,5051,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5051,1,3,0)
 ;;=3^Hyperparathyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,5051,1,4,0)
 ;;=4^E21.3
 ;;^UTILITY(U,$J,358.3,5051,2)
 ;;=^331438
 ;;^UTILITY(U,$J,358.3,5052,0)
 ;;=E78.5^^27^327^16
 ;;^UTILITY(U,$J,358.3,5052,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5052,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,5052,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,5052,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,5053,0)
 ;;=M10.30^^27^327^11
 ;;^UTILITY(U,$J,358.3,5053,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5053,1,3,0)
 ;;=3^Gout d/t Renal Impairment,Unspec Site
 ;;^UTILITY(U,$J,358.3,5053,1,4,0)
 ;;=4^M10.30
